Kravis Children's Pediatric Gastroenterology

Topics

• Inflammatory Bowel Disease 383
• Liver Disease Diagnosis and Treatment 44
• Pregnancy and Medication Impact 35
• Acute Lymphoblastic Leukemia research 18
• Gut microbiota and health 18
• Eosinophilic Esophagitis 17
• Pediatric Hepatobiliary Diseases and Treatments 16
• Celiac Disease Research and Management 15
• Organ Transplantation Techniques and Outcomes 14
• Adolescent and Pediatric Healthcare 13
• Liver Disease and Transplantation 11
• Pancreatitis Pathology and Treatment 10

Most cited

1. Crohn's disease.

   Lancet (London, England) · 2024 · 500 citations · Michael Dolinger

2. Understanding the therapeutic toolkit for inflammatory bowel disease.

   Nature reviews. Gastroenterology & hepatology · 2025 · 135 citations · Marla Dubinsky

3. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.

   Lancet (London, England) · 2023 · 318 citations · Marla Dubinsky

4. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.

   The New England journal of medicine · 2023 · 304 citations · Marla Dubinsky

5. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.

   Lancet (London, England) · 2022 · 368 citations · Marla Dubinsky

6. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.

   The New England journal of medicine · 2024 · 156 citations · Marla Dubinsky

7. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.